Bioavailable Silicon Composition Stable in Acidic pH
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of bioavailable silicon do not effectively exploit the synergistic effects of vitamins K2 and D3 for the treatment and prevention of osteoporosis and bone fragility, often requiring additional chemical stabilizers and lacking stability in acidic pH environments.
Innovation Solution
A composition comprising therapeutically effective amounts of bioavailable silicon, vitamin D3, and vitamin K2, which stabilize silicon and provide a synergistic effect without additional stabilizers, formulated in both liquid and solid oral forms to enhance bone health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If silicic acid and its derivatives are used in a strongly acidic pH environment, then the formulation maintains stability, but silicon condenses and polymerizes into polysilicic acids and hydrated silica which are poorly or not at all bioavailable
Solution Approach 1:
Vitamin K2 acts as a mediator that binds to silicon, forming a stable complex that prevents polymerization in acidic environments while maintaining bioavailability. The vitamin serves as an intermediary between the unstable silicic acid and the acidic gastric environment, protecting the silicon from condensation.
Solution Approach 2:
The invention creates a composite formulation where silicic acid is combined with vitamin K2 and vitamin D3. This composite structure leverages the stabilizing properties of the vitamins to maintain silicon in a bioavailable form, preventing the formation of non-bioavailable polysilicic acids and hydrated silica.
2Stability of the object's composition
If additional chemical stabilizers are added to prevent polymerization, then formulation stability is improved, but formulation costs increase
Solution Approach 1:
Vitamin K2 performs multiple functions: it stabilizes silicic acid against polymerization, enhances silicon bioavailability, and provides synergistic benefits for bone health alongside vitamin D3. This multi-functionality eliminates the need for separate stabilizer additives, reducing formulation costs while maintaining stability.
Solution Approach 2:
The formulation uses vitamin K2, which is already present as a nutritional component, to perform the stabilizing function. The vitamin serves itself by binding to silicon and preventing polymerization, eliminating the need for additional chemical stabilizers and reducing overall formulation costs.
3Ease of manufacture
If silicon is used in its most naturally occurring form (silica SiO2 or silicates), then the formulation is simple and natural, but the substances are poorly soluble and bioavailable to the gastrointestinal tract
Solution Approach 1:
The invention changes the chemical form of silicon from insoluble silica/silicates to soluble silicic acid derivatives. This parameter change in solubility and chemical structure dramatically improves gastrointestinal bioavailability while maintaining the natural origin of the silicon source.
Solution Approach 2:
The formulation creates a composite of silicic acid derivatives with vitamin K2 and vitamin D3, enhancing the bioavailability of silicon while maintaining formulation simplicity. The vitamin components facilitate absorption without complicating the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced therapeutic effects for osteoporosis prevention and bone fragility treatment by stabilizing silicon and leveraging the synergistic benefits of vitamins K2 and D3, while maintaining bioavailability and pH stability.
Implementation Method 1
vitamin K2 acts as a cofactor by promoting osteocalcin activation and contributing to bone mineralization through the binding of the same silicon
Implementation Method 2
vitamin D3 has a beneficial effect on bone collagen and promotes the decrease of calcium and phosphate in blood and soft tissue, promoting their reabsorption at the gastrointestinal level
Implementation Method 3
The absorbable and bioavailable form is that of silicic acid and its derivatives, such as organosilanolates
Data Source
AI summary
The present invention describes the combination of silicon in bioavailable form with vitamins K2 and D3 for the treatment and/or prevention of osteoporosis and dysfunction related to bone fragility.